Across a cohort of NSCLC patients, those with KEAP1/NRF2 mutant tumors had a nearly 60% rate of locoregional failure after chemoradiation relative to 20% in the KEAP1/NRF2 wildtype cohort [51]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.